BBIO Latest Press Releases

-- October 29, 2026 --

BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates Globe Newswire 4:01 PM

-- October 22, 2026 --

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET Globe Newswire 7:30 AM

-- October 16, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- October 11, 2026 --

Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records Globe Newswire 2:30 PM

Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 Globe Newswire 11:42 AM

-- October 6, 2026 --

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 Globe Newswire 4:01 PM

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting Globe Newswire 4:01 PM

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day PRNewswire 12:59 PM

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia Globe Newswire 7:30 AM

-- October 5, 2026 --

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day Globe Newswire 4:01 PM

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels Globe Newswire 7:30 AM

-- September 23, 2026 --

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening Globe Newswire 7:47 AM

-- September 18, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 9, 2026 --

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial Globe Newswire 4:00 AM

-- September 2, 2026 --

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 Globe Newswire 7:30 AM

-- September 1, 2026 --

BridgeBio to Participate in September Investor Conferences Globe Newswire 7:30 AM

-- August 31, 2026 --

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans Globe Newswire 3:44 PM

-- August 30, 2026 --

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM Globe Newswire 10:00 AM

-- August 26, 2026 --

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM Globe Newswire 7:30 AM

-- August 24, 2026 --

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026 Globe Newswire 7:30 AM

-- August 14, 2026 --

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base Globe Newswire 7:30 AM

-- August 13, 2026 --

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder Globe Newswire 5:42 PM

-- August 11, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- August 10, 2026 --

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates Globe Newswire 4:01 PM

-- August 3, 2026 --

BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET Globe Newswire 7:30 AM

-- July 22, 2026 --

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 Globe Newswire 7:30 AM

-- July 10, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- July 2, 2026 --

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM Globe Newswire 7:30 AM

-- July 1, 2026 --

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches Globe Newswire 7:30 AM

-- June 28, 2026 --

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia Globe Newswire 4:00 PM

-- June 23, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:31 PM

-- June 22, 2026 --

International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma Globe Newswire 9:05 AM

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026 Globe Newswire 7:30 AM